This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to German: Business Translation General field: Bus/Financial
Source text - English 1. BCG has surveyed investors every year since 2009 to understand their views on global equity markets and priorities for shareholder value creation.
There were 260 responses to the 2018 survey. Approximately 80% of the survey respondents were portfolio managers, and 20% were buy-side and sell-side analysts; 48% focused on the US, while most of the others focused on Europe or invested globally.
Collectively, these respondents directly manage more than $500 billion in assets and represent firms that manage $12 trillion to $15 trillion in assets.
2. Reflecting valuation concerns, investor expectations for total shareholder return (TSR) remain at historically low levels.
Survey respondents’ expectation for average annual TSR over the next three years was 5.6%.
By a ratio of approximately 2 to 1, investors reported spending more time making investment decisions, taking a more value-oriented approach, and exiting positions more quickly.
More than one-third (37%) of respondents said that they had adopted a slower and more deliberate investment approach over the past three years, compared with only about one-fifth (21%) who said that they had adopted a faster or more ad hoc approach.
Translation - German 1. BCG has surveyed investors every year since 2009 to understand their views on global equity markets and priorities for shareholder value creation. 1. BCG führt seit 2009 jedes Jahr eine Umfrage unter Anleger durch, um ihre Ansichten über die globalen Aktienmärkte und ihre Prioritäten bei der Wertschöpfung im Sinne der Aktionäre zu erfahren.
There were 260 responses to the 2018 survey. Approximately 80% of the survey respondents were portfolio managers, and 20% were buy-side and sell-side analysts; 48% focused on the US, while most of the others focused on Europe or invested globally. Die Umfrage 2018 wurde von 260 Personen beantwortet. Etwa 80 % der Befragten waren Portfoliomanager und 20 % Buy-Side- und Sell-Side-Analysten. Dabei konzentrierten sich 48 % auf die USA, während sich die meisten anderen auf Europa konzentrierten oder weltweit investierten.
Collectively, these respondents directly manage more than $500 billion in assets and represent firms that manage $12 trillion to $15 trillion in assets. Zusammengenommen verwalten diese Befragten mehr als 500 Milliarden Dollar an Vermögenswerten und repräsentieren Firmen, die 12 bis 15 Billionen Dollar an Vermögenswerten verwalten.
2. Reflecting valuation concerns, investor expectations for total shareholder return (TSR) remain at historically low levels. 2. Angesichts der Bewertungsbedenken bleiben die Erwartungen der Anleger an die Gesamtrendite für die Aktionäre (TSR) auf einem historisch niedrigen Niveau.
Survey respondents’ expectation for average annual TSR over the next three years was 5.6%. Die Umfrageteilnehmer erwarteten eine durchschnittliche jährliche Aktienrendite von 5,6 % für die nächsten drei Jahre.
By a ratio of approximately 2 to 1, investors reported spending more time making investment decisions, taking a more value-oriented approach, and exiting positions more quickly. Die Anleger gaben im Verhältnis von etwa 2 zu 1 an, dass sie sich mehr Zeit für ihre Anlageentscheidungen nehmen, einen stärker wertorientierten Ansatz verfolgen und Positionen schneller aufgeben.
More than one-third (37%) of respondents said that they had adopted a slower and more deliberate investment approach over the past three years, compared with only about one-fifth (21%) who said that they had adopted a faster or more ad hoc approach. Mehr als ein Drittel (37 %) der Befragten gab an, dass sie in den letzten drei Jahren einen langsameren und bewussteren Investitionsansatz gewählt haben, wohingegen nur etwa ein Fünftel (21 %) angab, dass sie einen schnelleren oder ad-hoc-Ansatz gewählt haben.
English to German: Pharma General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - English 3.1 Pharmacokinetics
The purpose of this study was to report the efficacy of topical cyclosporine 0.05% at a frequency of 3 to 4 times daily in severe dry eye disease.
We retrospectively identified a cohort of patients with severe dry eye disease who had shown inadequate response to at least a 4-month course of treatment with twice-daily use of topical cyclosporine 0.05% but who showed significant improvement to more frequent dosing.
Twenty-two patients, including 13 patients with ocular graft versus host disease and 9 patients with primary or secondary Sjögren’s syndrome, were included. After a minimum of a 2-month course of treatment with more frequent dosing of cyclosporine 0.05% (3 times a day in 7 patients and 4 times a day in 15 patients), overall dry eye symptoms were improved in 15 (68.2%) patients (9 patients with ocular graft versus host disease and 6 patients with Sjögren’s syndrome).
Mean corneal fluorescein staining scores (National Eye Institute scale of 0–15) improved (decreased) from the baseline (precyclosporine use) by −3.5 (range, 0 to −7) in patients with ocular graft versus host disease (P ≤ 0.0008) and −2.8 (range, 0 to −5) in patients with Sjögren’s syndrome (P ≤ 0.001).
After treatment with high-frequency use of cyclosporine 0.05%, the global physician assessment of dry eye status was favorable (improved) in 16 (72.7%) patients. Three (13.6%) patients reported new-onset symptoms of burning or irritation with the use of high-frequency dosing of topical cyclosporine. No other associated adverse effect was reported.
These data suggest that patients with severe dry eye may require more frequent dosing of topical cyclosporine 0.05% than twice daily.
Translation - German 3.1 Pharmakokinetik
Ziel dieser Studie war es, die Wirksamkeit von topischem Cyclosporin 0,05 % in einer Häufigkeit von 3 bis 4 Mal täglich bei schweren Formen des trockenen Auges zu untersuchen.
Wir haben retrospektiv eine Patientengruppe mit schweren Formen des trockenen Auges identifiziert, die auf eine mindestens viermonatige Behandlung mit zweimal täglicher Anwendung von topischem Cyclosporin 0,05 % nur unzureichend ansprachen, aber bei häufigerer Anwendung eine deutliche Verbesserung zeigten.
Zweiundzwanzig Patienten, darunter 13 Patienten mit okulärer Graft-versus-Host-Reaktion und 9 Patienten mit primärem oder sekundärem Sjögren-Syndrom, wurden in die Studie einbezogen. Nach einer mindestens zweimonatigen Behandlung mit häufigerer Anwendung von Cyclosporin 0,05 % (dreimal täglich bei 7 Patienten und viermal täglich bei 15 Patienten) verbesserten sich die Symptome des trockenen Auges bei 15 (68,2 %) Patienten (9 Patienten mit okulärer Graft-versus-Host-Reaktion und 6 Patienten mit Sjögren-Syndrom) insgesamt.
Die Mittelwerte der Fluorescein-Färbung der Hornhaut (Skala des National Eye Institute von 0-15) verbesserten (verringerten) sich im Vergleich zum Ausgangswert (vor der Einnahme von Cyclosporin) bei Patienten mit okulärer Graft-versus-Host-Reaktion um -3,5 (Bereich, 0 bis -7) (P ≤ 0,0008) und bei Patienten mit Sjögren-Syndrom um -2,8 (Bereich, 0 bis -5) (P ≤ 0,001).
Nach der Behandlung mit der hochfrequenten Anwendung von Cyclosporin 0,05 % war die Gesamtbeurteilung des Arztes zum Zustand des trockenen Auges bei 16 (72,7 %) Patienten günstig (verbessert). Drei (13,6 %) Patienten berichteten über neu aufgetretene Symptome wie Brennen oder Reizungen bei der hochfrequenten Anwendung von topischem Cyclosporin. Es wurden keine weiteren Nebenwirkungen gemeldet.
Diese Daten legen nahe, dass Patienten mit schweren Formen des trockenen Auges eine häufigere Anwendung von topischem Cyclosporin 0,05 % als zweimal täglich benötigen.
More
Less
Translation education
Master's degree - University of Giessen
Experience
Years of experience: 14. Registered at ProZ.com: Dec 2016. Became a member: Oct 2017.
AutoCAD, memoQ, MemSource Cloud, Microsoft Excel, Microsoft Office Pro, Microsoft Word, OmegaT, Powerpoint, Smartling, Trados Studio, Translation Workspace
Objective: Helping brands stand out in the German-speaking market
Recent Projects
Intellectual property: Patent applications and patent litigation documents in science and
technology;
Pharmaceutics: Regulatory texts: eCTDs of drugs;
Chemicals: Miscellaneous regulatory texts: Regulations on waste disposal; regulations on
exposure limits; regulations on food contact substances; hazard statements.
Medicine: Drug registration, Clinical histories of patients, Cancer
treatments.
Experience
2016: Translation Team Leader (supervising a team of 5 language
specialists and helping agencies acquire new clients and bigger projects
through successful test translations and pilot phases)
2016/17: 250 000 words of translation for Huawei in the field of
communication and cellular network technology
2017 - ongoing: 300 000 words of translation and proofreading of
technical patents & claims (+500 patents)
2016 - ongoing: Yearly 700 000 words of translation, including
translation projects for Deutsche Bank (financial), AMD & Xiaomi
(technology), Pfizer (medical research texts like cancer treatments,
medical devices)
I grew up bilingual, with German and Spanish being my mother tongues (to
be more precise, it's my mother’s tongue), so my passion for languages “wurde
mir in die Wiege gelegt”, as we like to say in German (I was born into the
trade). I started my bachelor's degree at Brandenburg University of Technology
Cottbus-Senftenberg (Germany) in Environmental Management, fully in English. To
be accepted, I passed my TOEFL (Test of English as a Foreign Language) with 98
points. My master's degree at the University of Giessen followed, gaining
extensive knowledge in the life sciences (bioinformatics, chemistry,
biomaterials, and biotechnology). After 14 years of translation experience, I
can proudly say that I have translated for some of the biggest companies,
spanning from tech companies like Huawei and AMD to financial companies like
Deutsche Bank and the health sector like Pfizer. I specialize in patent
translations and have so far translated over 500 patents. Furthermore, I have
worked with many translation agencies, helping them acquire big projects and
supervising the quality of the translations. It would be my pleasure to share
my knowledge with you.
Keywords: native german translator, german mother tongue, german translator, german translation, german translations, english german translator, spanish german translator, translations from english to german, translations from spanish to german, translation from english to german. See more.native german translator, german mother tongue, german translator, german translation, german translations, english german translator, spanish german translator, translations from english to german, translations from spanish to german, translation from english to german, translation from spanish to german, technical translation, technical translations, subtitle translation, subtitles translation, subtitles translations, patent translations, subtitle, subtitles, website translation, website translations, automotive translation, automotive translations, spain, english, german, technical, architecture, tourism, website, websites, germany, travel, transport, transport technology, spanisher übersetzer, englischer übersetzer, spanische übersetzung, spanische übersetzungen, englische übersetzung, englische übersetzungen, deutsche übersetzung, deutsche übersetzungen, übersetzer, übersetzerin, spanisch, deutsch, englisch, tourismus, reise, deutschland, webseite, webseiten, technik, untertitelung, reisen, architektur, civil, structural, engineering, Architektur, Bauwesen, Hochbau, Tiefbau, building materials, Baustoffe, aggregates, Zuschlagstoffe, cardiology, cardiac, heart surgery, Kardiologie, Herzchirurgie, medical, Medizin, pharma, legal, Recht, contracts, Verträge, business, Wirtschaft, finance, Finanzen, annual reports, Geschäftsberichte, financial statements, reporting, Jahresabschluss, Jahresabschlüsse, accounting, balance sheet, bilan, Bilanzierung, Bilanzen, Rechnungslegung, Rechnungswesen, Buchhaltung, Finanzberichterstattung, Immobilien, property, real estate, Fachübersetzungen, Electrical Engineer, Elektroingenieur PLC, SPS Speicherprogrammierbare Steuerungen Electrical Safety, Elektrische Sicherheit International Approvals, Internationale Zulassungen, Material Safety Data Sheets, Sicherheitsdatenblätter, Electrical Power Supply, Elektrische Stromversorgung, Railway installations, Eisenbahnanlagen, CE Conformity Declaration, CE-Konformitäts-Erklärung, Machinery, Maschinenbau, Railways - Eisenbahn Construction, Anlagenbau, Switchgears - Schaltanlagen Dentistry, Zahnheilkunde. See less.
Member since Oct '17
Portfolio